Search Results
Jun 03, 2026, 07:00 ET Phemex Expands TradFi Offering Beyond 70 Assets, Bringing Global Equities to 24/7 Crypto Markets
LLY) and Novo Nordisk (NVO) to global semiconductor and technology powerhouses like Samsung (SAMSUNG) and SK Hynix (
More news about: Phemex
Jun 03, 2026, 07:00 ET Phemex Expands TradFi Offering Beyond 70 Assets, Bringing Global Equities to 24/7 Crypto Markets
LLY) and Novo Nordisk (NVO) to global semiconductor and technology powerhouses like Samsung (SAMSUNG) and SK Hynix (
More news about: Phemex
May 12, 2026, 10:30 ET The $59B Quiet Shift Reshaping How Patients Access Care
structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).
More news about: Equity Insider
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 05, 2026, 17:07 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Feb 26, 2026, 15:18 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
than chronic insulin dependence is defining the strategic roadmaps of Avant Technologies, Inc. (OTCQB: AVAI), Novo Nordisk A/S (NYSE: NVO), Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Tandem Diabetes Care, Inc. (NASDAQ:
More news about: USA News Group
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
More news about: NOVO NORDISK INC.
Oct 01, 2025, 08:45 ET Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Sep 30, 2025, 16:41 ET NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Sep 29, 2025, 16:28 ET NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the important September 30, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Sep 29, 2025, 08:45 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO
Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
More news about: The Gross Law Firm
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Sep 26, 2025, 15:27 ET Novo Nordisk A/S (NVO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
NVO).
More news about: Glancy Prongay & Murray LLP
Sep 26, 2025, 09:00 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Sep 26, 2025, 08:19 ET CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit
More news about: Berger Montague
Sep 25, 2025, 08:45 ET The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
More news about: The Gross Law Firm
Sep 24, 2025, 16:55 ET Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
NVO) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Sep 24, 2025, 10:05 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) and reminds investors of the September 30, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP
Sep 23, 2025, 17:14 ET NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the
More news about: THE ROSEN LAW FIRM, P. A.
Sep 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Sep 22, 2025, 17:06 ET DEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S. (NYSE: NVO) ("Novo" or the "Company") following the filing of a securities class action lawsuit. The lawsuit was filed on behalf of investors who purchased
More news about: Berger Montague
Sep 22, 2025, 08:45 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO
Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
More news about: The Gross Law Firm
Sep 22, 2025, 05:07 ET NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
More news about: The Schall Law Firm